Also known as: J.P. Morgan, JPMorgan
BioNTech faces mixed analyst views as Bernstein initiates with a cautious Market Perform rating, while the company secures FDA Fast Track designation for BNT113 and prepares for a shareholder vote on capital restructuring and leadership transition.
JPMorgan downgraded Blue Jet Healthcare to Underweight with a ₹330 target price, citing weak contrast media execution, bempedoic acid competitive threats, and a thin late-stage pipeline with no launches expected for two years.
Moderna reported Q4 revenue of $678 million, beating analyst estimates, while posting a narrower-than-expected loss of $2.11 per share. The results came as the FDA refused to review the company's mRNA flu vaccine application.
